-
公开(公告)号:US20190247472A1
公开(公告)日:2019-08-15
申请号:US16063534
申请日:2016-12-16
发明人: Jinan LI
摘要: The present invention relates to the use of plasminogen in the dissolution of fresh and old thrombus. Compared with other existing thrombolytic drugs, the plasminogen of the present invention can specifically dissolve thrombus without causing side effects such as bleeding. The drug of the present invention also has the advantages of dissolving both fresh and old thrombus, with a long half-life and controllable thrombolytic strength. Therefore, plasminogen may become a brand-new strategy for dissolving thrombus in vivo.
-
公开(公告)号:US20190209708A1
公开(公告)日:2019-07-11
申请号:US16302222
申请日:2017-05-15
发明人: Botond ROSKA , Santiago ROMPANI
CPC分类号: A61K48/0058 , A61K48/00 , A61K48/005 , A61K48/0075 , A61P27/02 , C07K14/723 , C12N15/86 , C12N2750/14143
摘要: The present inventions relates to tools and methods for the treatment of blindness in a patient, wherein a vector comprising a gene coding for a light-sensitive molecule is injected into the lateral geniculate nucleus of the patient.
-
公开(公告)号:US20190192427A1
公开(公告)日:2019-06-27
申请号:US16327238
申请日:2017-08-23
申请人: Qinyuan ZHENG , BIOTOOL, LLC
发明人: Qinyuan ZHENG , Zeyidan JIAPAER
IPC分类号: A61K9/00 , A61K45/06 , A61K31/575 , A61K47/10 , A61K47/40 , A61K47/26 , A61K47/36 , A61K47/18 , A61P27/02 , A61P27/12 , A61K31/4174
CPC分类号: A61K9/0048 , A61K9/0053 , A61K31/047 , A61K31/41 , A61K31/4174 , A61K31/56 , A61K31/575 , A61K45/06 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/36 , A61K47/40 , A61P27/02 , A61P27/12
摘要: An ophthalmic pharmaceutical composition containing an azole compound, a method for preparing the same, as well as a use of the pharmaceutical composition in the preparation of an ophthalmic preparation for preventing and treating ophthalmic diseases. The ophthalmic preparation contains the azole compound at a concentration of 0.005-400 μM.
-
公开(公告)号:US20190185850A1
公开(公告)日:2019-06-20
申请号:US16326908
申请日:2017-08-21
发明人: Tara Moore , Andrew Nesbit , David Courtney , Katie Christie , Gene Lee
IPC分类号: C12N15/11 , C12N9/22 , A61K38/46 , A61K31/7088 , A61K9/00 , A61P27/02 , C07K14/315 , C07K14/195 , C07K14/495 , A61K35/545
CPC分类号: C12N15/11 , A01K67/0278 , A01K2207/15 , A01K2217/072 , A01K2227/105 , A01K2267/0306 , A61K9/0048 , A61K31/7088 , A61K35/545 , A61K38/465 , A61K48/00 , A61K48/005 , A61K48/0075 , A61P27/02 , C07K14/195 , C07K14/315 , C07K14/4741 , C07K14/495 , C12N9/22 , C12N15/85 , C12N2310/20 , C12N2320/32 , C12N2800/80 , C12Q1/68
摘要: The present disclosure relates to single guide RNA (sgRNA), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associate protein 9 (Cas9) system, and methods of use thereof for preventing, ameliorating or treating corneal dystrophies.
-
公开(公告)号:US20190169162A1
公开(公告)日:2019-06-06
申请号:US16303350
申请日:2017-06-01
IPC分类号: C07D401/10 , A61P27/02 , A61K9/00
CPC分类号: C07D401/10 , A61K9/0053 , A61K2121/00 , A61P27/02 , C07B2200/13
摘要: The invention provides new polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide, pharmaceutical compositions containing them and their use in therapy.
-
公开(公告)号:US20190091347A1
公开(公告)日:2019-03-28
申请号:US15767119
申请日:2015-10-11
发明人: Zheng-Rong Lu , Da Sun
IPC分类号: A61K48/00 , A61P27/02 , C07D211/88 , C12N15/11 , C12N15/113
CPC分类号: A61K48/0033 , A61K48/0075 , A61P27/02 , C07D211/88 , C12N15/111 , C12N15/113 , C12N15/87 , C12N2320/32
摘要: A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or includes a polymer, a targeting group, or a detectable moiety, and at least one of R4 and R5 includes a targeting group that targets and/or binds to a retinal or visual protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.
-
公开(公告)号:US20190015348A1
公开(公告)日:2019-01-17
申请号:US15743895
申请日:2016-07-12
申请人: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION , KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCE
发明人: Jeong Hun KIM , Dong Hyun JO , Tae Geol LEE
CPC分类号: A61K9/51 , A61K9/0048 , A61K9/146 , A61K9/16 , A61K9/5052 , A61K9/5169 , A61K33/00 , A61K33/24 , A61K38/385 , A61K47/42 , A61K47/6923 , A61K47/6925 , A61P27/00 , A61P27/02 , B82Y5/00 , B82Y30/00 , G01N33/15 , G01N33/50 , G01N33/68
摘要: Provided is a nanoparticle-vitreous body-based protein complex, and more particularly, to a composition for inhibiting angiogenesis which includes the complex as an active ingredient, and a composition for preventing or treating an angiogenesis-related disease or a retinal disease. When the nanoparticle-vitreous body-based protein complex according to the subject matter is locally injected into the vitreous body, the complex exhibits significantly excellent binding strength with a vascular endothelial growth factor and thus can inhibit angiogenesis, thus being easily used to prepare a therapeutic agent for preventing, alleviating, or treating retinal and choroidal angiogenesis-related diseases.
-
8.
公开(公告)号:US20180355030A1
公开(公告)日:2018-12-13
申请号:US15775550
申请日:2016-11-12
发明人: William GREENE , Kirk DORNBUSH , Thi-Sau MIGONE , Gabriela BURIAN
IPC分类号: C07K16/22 , C07K14/745 , A61K39/395 , A61K47/64 , A61P35/00 , A61P27/02
CPC分类号: C07K16/22 , A61K39/39541 , A61K47/64 , A61K2039/505 , A61P27/02 , A61P35/00 , C07K14/745 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要: Provided herein are immunoconjugate dimers for the treatment of disorders associated with neovascularization and tumor-associated neovascularization (e.g ocular melanoma) and symptoms associated with the same. The methods comprises administering to the patient in one or more dosing sessions, a composition comprising an effective amount of any one or more of the immunoconjugate dimers of the invention, wherein the monomer subunits of the dimer each comprises a mutated factor VIIa (FVIIa) protein conjugated to a immunoglobulin G1 (IgG1) Fc domain.
-
公开(公告)号:US20180353620A1
公开(公告)日:2018-12-13
申请号:US16109630
申请日:2018-08-22
申请人: EyeServ GmbH
CPC分类号: A61K48/0058 , A61K48/0066 , A61K48/0075 , A61P27/02 , C12N9/16 , C12N2750/14143 , C12N2799/025 , C12N2830/008
摘要: The present invention relates to a polynucleotide configured for the treatment of a retinal degeneration disease, such as retinitis pigmentosa (RP), a nucleic acid vector comprising said polynucleotide, a pharmaceutical composition comprising said nucleic acid vector, a kit comprising said polynucleotide or said nucleic acid vector, a method of making said nucleic acid vector, and a method for treating a retinal degeneration disease.
-
公开(公告)号:US20180344672A1
公开(公告)日:2018-12-06
申请号:US15992262
申请日:2018-05-30
发明人: Kenji EGUSA , Takuma KATAYAMA , Kazutoshi YOKOYAMA , Remko Alexander BAKKER , Ngai Hang Victor CHONG , Joerg RIPPMANN
IPC分类号: A61K31/166 , A61K9/20 , A61P27/02 , A61P1/16
CPC分类号: A61K31/166 , A61K9/2013 , A61K9/2018 , A61K9/2059 , A61P1/16 , A61P3/00 , A61P27/02 , A61P29/00 , A61P35/00
摘要: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
-
-
-
-
-
-
-
-
-